Fig. 2: Kaplan–Meier estimates of survival curves for AP and GP groups. | Nature Communications

Fig. 2: Kaplan–Meier estimates of survival curves for AP and GP groups.

From: A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer

Fig. 2

Kaplan–Meier plot of PFS (A) and OS (B). Data for the ITT population. Treatment effects were compared using the log-rank test; HRs and corresponding 95% CIs were estimated using Cox-proportional-hazard regression model. P values are one-sided with no adjustment for multiplicity. HR = hazard ratio.

Back to article page